Metact Combination Tablets special drug use surveillance Survey on long-term use for type 2 diabetes mellitus

TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 1,000 人开始时间: 2013年12月4日最近更新: 2023年10月17日

试验速览

暂无简介。

•Patients with type 2 diabetes mellitus for whom a physician has concluded that therapy with pioglitazone hydrochloride combined with metformin hydrochloride is appropriate and for whom long-term treatment with Metact Combination Tablets is considered necessary.

•Patients for whom pioglitazone hydrochloride and metformin hydrochloride are contraindicated.
•(1) Patients with cardiac insufficiency or a history of cardiac insufficiency
•(2) Patients with the following conditions
•(i) Patients with a history of lactic acidosis
•(ii) Dialysis patients (including peritoneal dialysis)
•(iii) Patients with cardiovascular conditions such as shock, cardiac insufficiency, myocardial infarction, and pulmonary embolism; patients with severely impaired pulmonary function; and patients with other conditions fostering susceptibility to hypoxemia
•(iv) Patients with excessive alcohol consumption
•(v) Patients with dehydration
•(vi) Patients with gastrointestinal disorders such as diarrhea and vomiting
•(vii) Elderly patients
•(3) Patients with renal impairment (including mild renal impairment)
•(4) Patients with hepatic impairment
•(5) Patients with severe ketosis, diabetic coma or pre-coma, or type I diabetes mellitus
•(6) Patients with severe infection, severe trauma, or pre- and post-operative patients
•(7) Patients who are malnourished, starved, debilitated, or have pituitary gland insufficiency or adrenal gland insufficiency
•(8) Patients with a history of hypersensitivity to the ingredients in Metact Combination Tablets or biguanides
•(9) Pregnant or potentially pregnant women

发起方

TAKEDA PHARMACEUTICAL COMPANY LTD.